Vijaya Diagnostic Centre Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 200% at ₹2/Share	16-Sep-2026	16-Sep-2026
DividendsFinal Dividend of 200% at ₹2/Share	29-Aug-2025	29-Aug-2025
DividendsFinal Dividend of 100% at ₹1/Share	30-Aug-2024	30-Aug-2024

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Kotak Small Cap Fund - Growth	54.55 Lac	54.55 Lac no change
HDFC Small Cap Fund - Regular Plan - Growth	46.16 Lac	46.16 Lac no change
Nippon India Multi Cap Fund - Growth	29.14 Lac	29.14 Lac no change
HSBC Small Cap Fund - Regular Plan - Growth	25.04 Lac	25.04 Lac no change
Axis Small Cap Fund - Regular Plan - Growth	20.62 Lac	20.62 Lac no change

Ankush

13 Oct • 9:55 AM · SEBI-Registered Analyst

EXPERTS INDICATE BULLISH ON Lal PathLabs Ltd.

LALPATHLAB

Axis Direct has maintained a bullish stance on Dr Lal PathLabs, Vijaya Diagnostic Centre and Nephrocare Health Services, assigning ‘Buy’ ratings to all three stocks. The brokerage’s target prices indicate potential upside of up to 21%, supported by structural growth opportunities in India’s healthcare and diagnostics sector. For Vijaya Diagnostic Centre, Axis Direct has set a target price of Rs 1,730, indicating an upside of around 20% from the current market price of Rs 1,437. The company operates more than 140 centres across South India, offering pathology testing and advanced radiology services, including MRI, CT and PET-CT scans. The brokerage highlighted the company’s strong customer retention and healthy EBITDA margins of approximately 39%-40% as key strengths. For Nephrocare Health Services, which operates under the NephroPlus brand, Axis Direct has assigned a target price of Rs 750, implying an upside of around 21% from the current market price of Rs 616. The company is India’s and Asia’s largest specialised dialysis service provider, with 490 clinics across 269 cities in India, the Philippines, Uzbekistan and Nepal. Its network comprises 255 captive hospital clinics, 176 public-private partnership (PPP) clinics and 59 standalone centres. The brokerage also highlighted improving cash generation and capital efficiency across the organised healthcare and diagnostics sector. Operating cash flow as a proportion of EBITDA has reached 70%-80% or higher, while return on capital employed continues to improve. Combined with minimal net leverage, these factors are strengthening the financial profiles of healthcare and diagnostic companies and supporting their valuations.

TrueNorth Capital

25 Sep • 1:26 PM · SEBI-Registered Analyst

Vijaya Diagnostic enters North-East via Arya Wellness

Vijaya Diagnostic Centre [

VIJAYA

] has acquired 100% of Assam-based Arya Wellness Centre for ~₹46 crore to launch its regional footprint. The target business reported ₹26 crore revenue and ₹5.6 crore EBITDA for FY26. This acquisition offers Vijaya Diagnostic Centre a direct entry into the under-penetrated North-East market using an established hub in Guwahati. The business fits Vijaya's high-margin B2C preference, as over 85% of Arya Wellness's revenue comes directly from individual customers rather than institutional channels. It also provides immediate earnings support without balance sheet strain, since the transaction was funded entirely through internal cash reserves at an enterprise valuation of 8–9x FY26 EBITDA. The key issue is whether this initial anchor can support long-term regional density. While the transaction valuation appears reasonable, Vijaya Diagnostic Centre trades at a premium of ~33x FY28e EV/EBITDA following a 74% stock price rally over the last 6 months. High market valuations leave little room for operational delays or integration issues as the company expands its network beyond its core Southern markets. Investors should track network execution across new geographies, specifically the planned addition of 9 hubs and 10–12 spokes in FY27, along with the retention of local margin profiles near the target 40% EBITDA guidance. We maintain a cautious Equal-weight view on the stock at current market levels due to stretched valuations, despite strong operational execution. Disclosure: Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vivek kumar

24 Sep • 4:47 PM · SEBI-Registered Analyst

Vijaya Diagnostic Centre breaks above ₹1,550 resistance!

Vijaya Diagnostic Centre breaks above ₹1,550 resistance Vijaya Diagnostic Centre Limited (NSE: VIJAYA) is trading around ₹1,570.70 after breaking above the crucial ₹1,550 resistance zone and moving into fresh all-time-high territory. The breakout follows a period of consolidation and is supported by improving trading volumes. The stock continues to maintain a higher-high and higher-low structure and is trading above its key moving averages. RSI is holding above 60, indicating that short-term momentum has strengthened alongside the price breakout. Why it matters ₹1,550 was the important resistance level. The move above this zone changes the immediate chart structure and makes the previous resistance an important support reference. My view My view is that the breakout needs to sustain above ₹1,550. Holding this zone during any short-term consolidation would provide stronger confirmation of the move.

RAJIV GUPTA (SEBI RA)

13 Sep • 3:38 PM · SEBI-Registered Analyst

100% acquisition of the integrated diagnostic business

Code BSE: 543350 NSE:

VIJAYA

Vijaya Diagnostic Centre Makes Strategic Foray into Assam, Strengthening its Eastern India Presence through the Acquisition of B2C Focused Integrated Diagnostic Centre, Arya Wellness Centre in Guwahati Commenting on the acquisition, Ms. Suprita Reddy, Managing Director & CEO, Vijaya Diagnostic Centre Limited, said: Our entry into Guwahati marks another important milestone in Vijaya’s journey towards building a highquality, integrated diagnostics network. We have consistently pursued a disciplined approach to expansion, focusing on markets with strong long-term demand for comprehensive and advanced diagnostic services. Guwahati is a natural strategic extension of our growing presence in West Bengal and provides an attractive gateway to the North-East. Arya Wellness Centre has been built on an ethos that closely aligns with Vijaya’s philosophy of delivering high-quality diagnostics. It is a unique asset in Guwahati with a balanced mix of advanced and basic pathology and radiology services, making it a strategically attractive asset for us. We believe this acquisition provides Vijaya with a strong platform to establish a meaningful presence in Assam and progressively expand across the North-Eastern region.

Akhilesh Jat SEBI RA

8 Aug • 9:06 PM · SEBI-Registered Analyst

🔬 Vijaya Diagnostic Faces Volatile Session Despite Strong Q1 Performance

On 7 August 2026,

VIJAYA

witnessed sharp intraday volatility following its Q1 FY27 earnings announcement. The stock initially rallied nearly 4.6% as investors reacted positively to the results, but the momentum faded through the session. The stock eventually slipped into negative territory, closing 1.37% lower on Friday and ending almost 3.8% below its intraday high. 📊 Q1 FY27 Highlights (Consolidated YoY): • Profit surged 37.6% to ₹53.1 crore from ₹38.6 crore. • Revenue jumped 22.8% to ₹231 crore from ₹188 crore. While the strong earnings triggered early buying interest, profit-booking and broader market dynamics weighed on the stock later in the day. Despite the volatile session, Vijaya Diagnostic has remained a notable outperformer in CY2026, with the stock advancing more than 27% year-to-date. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

PATEL ABHIKUMAR HARESHBHAI

13 Jul • 11:55 AM · SEBI-Registered Analyst

Daily Index View : NIFTY50 as on 13/07/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 5% 🔍 Key Level to Watch: 24099 🔄 Current Market Surface: The trend will stay Positive until the market stay above 24099 That’s 108 points away from the last day Closing Price of 24207 ATR 268 2. Demand & Supply PROBABILITY Force is Demand & Supply is High 15% Last 3 days market has been flatish compared to ATR, so demand has very strong firepower — it just needs sentiment support 10 Jul 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) +2,603.72 +2,019.68 3. Reflexivity PROBABILITY First Half is Mildly Supportive to Bullish Momentum for at least first half 5% Last day market rallied Intraday around 25–50% of the 8-day average ATR, so it should keep its momentum intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by 14 -42% Dow jones future (live) 52,724 Up/Donw by -182 Hang seng (Live) 24175 Up/Donw by -64 Nikki 225 (Live) 67187 Up/Donw by -1,371 Sentiments: Dow Jones Futures is Trading Flat to Negative & HANG SENG Index is trading Flat to Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout

VIJAYA

Vijaya Diagnostic Centre Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Vijaya Diagnostic Centre Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Vijaya Diagnostic Centre Ltd.?

What is the market cap of Vijaya Diagnostic Centre Ltd.?

Should I buy Vijaya Diagnostic Centre Ltd. stock now?

What is the 52 week high and low of Vijaya Diagnostic Centre Ltd.?

Is the Vijaya Diagnostic Centre Ltd. stock good to buy?

Is Vijaya Diagnostic Centre Ltd. a good buy for the long term?

Is Vijaya Diagnostic Centre Ltd. overvalued or undervalued?

What is the PE and PB ratio of Vijaya Diagnostic Centre Ltd.?